Study PXN110748: An Efficacy and Safety Study of XP13512 [gabapentin enacarbil] Compared With a Concurrent Placebo Control in Subjects With Neuropathic Pain Associated With Post-Herpetic Neuralgia (PHN)

Trial Profile

Study PXN110748: An Efficacy and Safety Study of XP13512 [gabapentin enacarbil] Compared With a Concurrent Placebo Control in Subjects With Neuropathic Pain Associated With Post-Herpetic Neuralgia (PHN)

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2016

At a glance

  • Drugs Gabapentin enacarbil (Primary)
  • Indications Neuropathic pain; Postherpetic neuralgia
  • Focus Registrational; Therapeutic Use
  • Sponsors XenoPort
  • Most Recent Events

    • 03 May 2014 Results of an analysis of sensitivity analyses based on secondary endpoints presented at the 33rd Annual Scientific Meeting of the American Pain Society.
    • 03 May 2014 Results of an analysis of sensitivity analyses based on the primary endpoint presented at the 33rd Annual Scientific Meeting of the American Pain Society.
    • 07 Jun 2012 Results from this trial were used to support approval of gabapentin enacarbil for the treatment of postherpetic neuralgia in the US.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top